This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (79)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Thrombolysis  • Adverse Effects  • Medication Error  • Alert me on articles by topic

Karen P. Alexander, MD; Anita Y. Chen, MS; Matthew T. Roe, MD, MHS; L. Kristin Newby, MD, MHS; C. Michael Gibson, MD; Nancy M. Allen-LaPointe, PharmD; Charles Pollack, MD; W. Brian Gibler, MD; E. Magnus Ohman, MD; Eric D. Peterson, MD, MPH; for the CRUSADE Investigators

JAMA. 2005;294:3108-3116.

Context  Effective medical care assumes delivery of evidence-based medicines to appropriate patients with doses comparable to those studied.

Objective  To investigate dosing of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and glycoprotein IIb/IIIa inhibitors, and the association between dosing and major outcomes.

Design, Setting, and Participants  A prospective observational analysis in 387 US academic and nonacademic hospitals of 30 136 patients from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative Registry who had non–ST-segment elevation acute coronary syndromes (NSTE ACS) with chest pain and either positive electrocardiograms or cardiac biomarkers between January 1 and September 30, 2004.

Main Outcome Measures  Excessive dosing of UFH, LMWH, and glycoprotein IIb/IIIa inhibitors and major clinical outcomes, including bleeding, in-hospital mortality, and length of stay.

Results  A total of 3354 patients (42%) with NSTE ACS who were administered antithrombotic agents received at least 1 initial dose outside the recommended range. An excess dose was administered to 2934 patients (32.8%) treated with UFH, 1378 (13.8%) treated with LMWH, and 2784 (26.8%) treated with glycoprotein IIb/IIIa inhibitors. Factors associated with excess dosing included older age, as well as female sex, renal insufficiency, low body weight, diabetes mellitus, and congestive heart failure. Relative to those patients not administered excess dosages, patients with excess dosages of UFH, LMWH, and glycoprotein IIb/IIIa inhibitors either tended toward or had higher risks for major bleeding (adjusted odds ratio [OR], 1.08; 95% confidence interval [CI], 0.94-1.26; OR, 1.39; 95% CI, 1.11-1.74; and OR, 1.36; 95% CI, 1.10-1.68; respectively). Bleeding increased relative to the degree of excess dose and to the number of agents administered in excess (6.6% [237/3590] if neither heparin nor glycoprotein IIb/IIIa excess vs 22.2% [93/419] if both excess). Mortality and length of stay were also higher among those patients administered excess dosing. We estimated that 15% (400/2766) of major bleeding in this population may be attributable to excess dosing.

Conclusions  Patients with NSTE ACS treated in the community often receive excess doses of antithrombotic therapy. Dosing errors occur more often in vulnerable populations and predict an increased risk of major bleeding.

Author Affiliations: Duke University Medical Center, Duke Clinical Research Institute, Durham, NC (Drs Alexander, Roe, Newby, Allen-LaPointe, Ohman, and Peterson, and Ms Chen); Harvard Clinical Research Institute, Boston, Mass (Dr Gibson); University of Pennsylvania School of Medicine, Philadelphia (Dr Pollack); and University of Cincinnati College of Medicine, Cincinnati, Ohio (Dr Gibler).

RELATED LETTERS

Excess Dosing of Antithrombotic Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
Andrew T. Yan, Raymond T. Yan, and Shaun G. Goodman
JAMA. 2006;295(16):1896.
EXTRACT | FULL TEXT  

Excess Dosing of Antithrombotic Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
Frédéric Lapostolle, Jean Catineau, Claude Lapandry, and Frédéric Adnet
JAMA. 2006;295(16):1896-1897.
EXTRACT | FULL TEXT  

Excess Dosing of Antithrombotic Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
David Parra, Daniel Woods, Venkataraman Balu, and Roy Coakley
JAMA. 2006;295(16):1897.
EXTRACT | FULL TEXT  

Excess Dosing of Antithrombotic Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes—Reply
Karen P. Alexander and Eric D. Peterson
JAMA. 2006;295(16):1897.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes
Budaj et al.
Eur Heart J 2008;0:ehn358v1-7.
ABSTRACT | FULL TEXT  

Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial
Lopes et al.
Eur Heart J 2008;29:1827-1833.
ABSTRACT | FULL TEXT  

Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease
Chan et al.
J Am Coll Cardiol Intv 2008;1:369-378.
ABSTRACT | FULL TEXT  

Introduction
Haines
Am J Health Syst Pharm 2008;65:S3-S4.
FULL TEXT  

Considerations in using anticoagulant therapy in special patient populations
Phillips et al.
Am J Health Syst Pharm 2008;65:S13-S21.
ABSTRACT | FULL TEXT  

Outcomes Research: Generating Evidence for Best Practice and Policies
Krumholz
Circulation 2008;118:309-318.
FULL TEXT  

Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT | FULL TEXT  

Bleeding and transfusion in acute coronary syndromes: a shift in the paradigm
Bassand
Heart 2008;94:661-666.
FULL TEXT  

Clinical benefit and practical use of fondaparinux in the invasive management of patients with acute coronary syndromes
Mehta
Eur Heart J Suppl 2008;10:C14-C21.
ABSTRACT | FULL TEXT  

Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
Melloni et al.
J Am Coll Cardiol 2008;51:991-996.
ABSTRACT | FULL TEXT  

Patient Outcomes After Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Venous Thromboembolism Study
Spencer et al.
Arch Intern Med 2008;168:425-430.
ABSTRACT | FULL TEXT  

Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.
Ndrepepa et al.
J Am Coll Cardiol 2008;51:690-697.
ABSTRACT | FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
American College of Cardiology/American Heart Asso et al.
J Am Coll Cardiol 2008;51:172-209.
FULL TEXT  

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
King et al.
Circulation 2008;117:261-295.
FULL TEXT  

Measuring the Quality of Primary PCI for ST-Segment Elevation Myocardial Infarction: Time for Balance
Masoudi
JAMA 2007;298:2790-2791.
FULL TEXT  

Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?
Spencer et al.
Circulation 2007;116:2793-2801.
ABSTRACT | FULL TEXT  

The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2007;50:2254-2262.
FULL TEXT  

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Wiviott et al.
NEJM 2007;357:2001-2015.
ABSTRACT | FULL TEXT  

Impact of Female Sex on Death and Bleeding After Fibrinolytic Treatment of Myocardial Infarction in GUSTO V
Reynolds et al.
Arch Intern Med 2007;167:2054-2060.
ABSTRACT | FULL TEXT  

Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes
Fox et al.
ANN INTERN MED 2007;147:304-310.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT  

Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach
Nikolsky et al.
Eur Heart J 2007;28:1936-1945.
ABSTRACT | FULL TEXT  

Enoxaparin Dosing and Associated Risk of In-Hospital Bleeding and Death in Patients With Non ST-Segment Elevation Acute Coronary Syndromes
LaPointe et al.
Arch Intern Med 2007;167:1539-1544.
ABSTRACT | FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

Women, Acute Ischemic Heart Disease, and Antithrombotic Therapy: Challenges and Opportunities
Harrington
Circulation 2007;115:2796-2798.
FULL TEXT  

Impact of anaemia, bleeding, and transfusions in acute coronary syndromes: a shift in the paradigm
Bassand
Eur Heart J 2007;28:1273-1274.
FULL TEXT  

Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2549-2569.
ABSTRACT | FULL TEXT  

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Rao et al.
Eur Heart J 2007;28:1193-1204.
ABSTRACT | FULL TEXT  

Characteristics, Management, and Outcomes of 5,557 Patients Age >=90 Years With Acute Coronary Syndromes: Results From the CRUSADE Initiative
Skolnick et al.
J Am Coll Cardiol 2007;49:1790-1797.
ABSTRACT | FULL TEXT  

Optimal Timing for Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: Questions, Answers, and More Questions
Mahaffey and Harrington
JAMA 2007;297:636-639.
FULL TEXT  

The Year in Epidemiology, Health Services Research, and Outcomes Research
Krumholz and Masoudi
J Am Coll Cardiol 2006;48:1886-1895.
FULL TEXT  

Registries and surveys in acute coronary syndrome
Fox
Eur Heart J 2006;27:2260-2262.
FULL TEXT  

Bleeding and management of bleeding
Eikelboom and Hirsh
Eur Heart J Suppl 2006;8:G38-G45.
ABSTRACT | FULL TEXT  

Small-Molecule Glycoprotein IIb/IIIa Antagonists and Bleeding Risk in Women: Too Much of a Good Thing?
Leopold
Circulation 2006;114:1344-1346.
FULL TEXT  

Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative
Alexander et al.
Circulation 2006;114:1380-1387.
ABSTRACT | FULL TEXT  

Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes
Eikelboom et al.
Circulation 2006;114:774-782.
ABSTRACT | FULL TEXT  

The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
Giugliano and Braunwald
J Am Coll Cardiol 2006;48:386-395.
FULL TEXT  

The Future of an Illusion
Bittl
J Am Coll Cardiol 2006;47:2380-2383.
FULL TEXT  

Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide: Observations From the PROTECT-TIMI-30 Trial
Kirtane et al.
J Am Coll Cardiol 2006;47:2374-2379.
ABSTRACT | FULL TEXT  

Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
Yan et al.
JAMA 2006;295:1896-1896.
FULL TEXT  

Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
Parra et al.
JAMA 2006;295:1897-1897.
FULL TEXT  

Excess dosing of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes.
Lapostolle et al.
JAMA 2006;295:1896-1897.
FULL TEXT  

Therapy for Patients with Acute Coronary Syndromes -- New Opportunities
Gibbons and Fuster
NEJM 2006;354:1524-1527.
FULL TEXT  

Fondaparinux in ST-Segment Elevation Myocardial Infarction: The Drug, the Strategy, the Environment, or All of the Above?
Califf
JAMA 2006;295:1579-1580.
FULL TEXT  

Overdosing of Antithrombotic Meds for Non-STE ACS Increases Bleeding and Death
JWatch Emergency Med. 2006;2006:2-2.
FULL TEXT  

How Common Is Excess Medication Dosing After NSTEACS?
Journal Watch Cardiology 2006;2006:1-1.
FULL TEXT